Tablets:  90 mg or 30 mg.

1.INDICATIONS AND USAGE 

Brigatinib is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

2.WARNINGS

Interstitial Lung Disease (ILD)/Pneumonitis

Hypertension

Bradycardia

Visual Disturbance

Creatine Phosphokinase (CPK) Elevation